HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Richard Lock Selected Research

Glioblastoma (Glioblastoma Multiforme)

1/2014Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
5/2013Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.
8/2012Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
4/2012Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program.
6/2008Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Richard Lock Research Topics

Disease

42Neoplasms (Cancer)
01/2017 - 01/2007
10Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/2017 - 04/2006
10Leukemia
08/2013 - 04/2006
7Neuroblastoma
01/2017 - 06/2008
5Glioblastoma (Glioblastoma Multiforme)
01/2014 - 06/2008
5Osteosarcoma (Osteogenic Sarcoma)
12/2012 - 06/2008
5Rhabdomyosarcoma
08/2012 - 06/2008
4Ewing Sarcoma (Sarcoma, Ewing)
04/2011 - 06/2008
3Hypoxia (Hypoxemia)
08/2012 - 01/2011
3Rhabdoid Tumor (Rhabdoid Tumors)
12/2009 - 06/2008
2Wilms Tumor (Wilm's Tumor)
08/2012 - 12/2009
1COVID-19
01/2020
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2016
1Carcinogenesis
01/2013
1Myeloid Leukemia (Leukemia, Myelocytic)
10/2012
1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)
08/2012
1Lymphoma (Lymphomas)
04/2012
1Inflammation (Inflammations)
10/2011
1Hyperalgesia
10/2011
1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
06/2011
1Astrocytoma (Pilocytic Astrocytoma)
10/2010
1Breast Neoplasms (Breast Cancer)
10/2009
1Alveolar Rhabdomyosarcoma
07/2008
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
06/2008
1Carcinoma (Carcinomatosis)
06/2008

Drug/Important Bio-Agent (IBA)

22N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA
01/2017 - 12/2007
4Proteins (Proteins, Gene)FDA Link
01/2013 - 04/2006
2Vincristine (Oncovin)FDA LinkGeneric
08/2013 - 12/2007
2Transcription Factors (Transcription Factor)IBA
01/2013 - 06/2011
2Messenger RNA (mRNA)IBA
02/2012 - 04/2006
2ProdrugsIBA
09/2011 - 01/2011
2PR-104IBA
09/2011 - 01/2011
2Pharmaceutical PreparationsIBA
07/2008 - 01/2007
1Anesthetics (Anesthetic Agents)IBA
01/2020
1CBLC137IBA
01/2017
1selinexorIBA
02/2016
1Exportin 1 ProteinIBA
02/2016
1Caspase 8 (Caspase-8)IBA
01/2016
1Inhibitor of Apoptosis ProteinsIBA
01/2016
1birinapantIBA
01/2016
1CaspasesIBA
01/2016
13- (2- (2- tert- butylphenylaminooxalyl)aminopropionylamino)- 4- oxo- 5- (2,3,5,6- tetrafluorophenoxy)pentanoic acidIBA
01/2016
1talazoparibIBA
01/2015
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2015
1sapanisertibIBA
08/2014
1quisinostatIBA
02/2014
1Polo-Like Kinase 1IBA
01/2014
1BI 6727IBA
01/2014
1eribulinFDA Link
08/2013
1Antimitotic AgentsIBA
08/2013
1DNA (Deoxyribonucleic Acid)IBA
05/2013
1XL147IBA
05/2013
1Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
05/2013
1Temozolomide (Temodar)FDA LinkGeneric
05/2013
1Nuclear Proteins (Protein, Nuclear)IBA
01/2013
1dinaciclibIBA
12/2012
1SGI 1776IBA
10/2012
1MK 2206IBA
09/2012
1JNJ 26854165IBA
08/2012
1pevonedistatIBA
08/2012
1EverolimusFDA Link
08/2012
1Glucose (Dextrose)FDA LinkGeneric
08/2012
1(2,4- dihydroxy- 5- isopropylphenyl)- (5- (4- methylpiperazin- 1- ylmethyl)- 1,3- dihydroisoindol- 2- yl)methanoneIBA
07/2012
12,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA
05/2012
1LCL161IBA
04/2012
1Mechanistic Target of Rapamycin Complex 2IBA
02/2012
1Mechanistic Target of Rapamycin Complex 1IBA
02/2012
1Topotecan (Hycamtin)FDA LinkGeneric
02/2012
1Genz-644282IBA
02/2012
1(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA
02/2012
1Lenalidomide (CC 5013)FDA Link
10/2011
1Aldo-Keto ReductasesIBA
09/2011
1PR-104AIBA
09/2011
1Oxidoreductases (Dehydrogenase)IBA
09/2011
1Aldo-Keto Reductase Family 1 Member C3IBA
09/2011
1PolyaminesIBA
08/2011
1SpermineIBA
08/2011
1BMS 754807IBA
04/2011
1Phosphotransferases (Kinase)IBA
12/2010
1Sorafenib (BAY 43-9006)FDA Link
12/2010
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
12/2010
1AZD 6244IBA
10/2010
1MLN 8237IBA
07/2010
1mapatumumabIBA
02/2010
1ispinesibIBA
12/2009
1Tyrosine Kinase InhibitorsIBA
10/2009
1Lapatinib (GW572016)FDA Link
10/2009
1plitidepsin (aplidine)IBA
09/2009
117- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA
07/2008
1Sunitinib (Sutent)FDA Link
07/2008
1Antineoplastic Agents (Antineoplastics)IBA
07/2008
1robatumumabIBA
06/2008
1ABT-737IBA
06/2008
1navitoclaxIBA
06/2008
1Insulin-Like PeptidesIBA
06/2008

Therapy/Procedure

3Drug Therapy (Chemotherapy)
01/2016 - 08/2012
2Therapeutics
08/2013 - 01/2011
2Withholding Treatment
07/2008 - 06/2008
1Radiotherapy
05/2013
1Duration of Therapy
07/2010